home All News open_in_new Full Article

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

ZUNVEYL is the first oral FDA-approved treatment for Alzheimer’s disease in the past decade 32 person sales team hired to cover the $2 billion Long-Term-Care market All launch activities delivered on-time and on-budget, positioning ZUNVEYL for success VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments […]


today 17 h. ago attach_file Economics

attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Culture
attach_file Sport
attach_file Events
attach_file Sport
attach_file Other
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other


ID: 3593978095
Add Watch Country

arrow_drop_down